Zicam Case Shows FDA Takes Defining Adverse Events Seriously
This article was originally published in The Tan Sheet
Executive Summary
Narrowly interpreting the definition of serious adverse events - compared to FDA's approach - is already costing Matrixx Initiatives at least $10 million dollars with the recall of its intranasal Zicam products